JNK India Q1FY27: consolidated PAT up sharply YoY to ₹9.6 Cr on 81% revenue growth
PAT +754.05% YoY · revenue +81.48% · margins expanding
₹179.96 Cr
+81.48% YoY
₹9.63 Cr
+754.05% YoY
5.17%
+4.1pp YoY
₹2.05
JNK India's consolidated Q1FY27 revenue came in at ₹179.96 Cr, up 81.5% YoY from ₹99.17 Cr but down 46.8% QoQ from a blowout ₹338.44 Cr in Q4FY26. Consolidated PAT (profit for the period) was ₹9.63 Cr — roughly 8.5x the ₹1.13 Cr posted a year ago, but down 70.9% sequentially from ₹33.04 Cr; basic EPS was ₹2.05 versus ₹0.20 YoY and ₹5.84 QoQ. The YoY jump is the headline, but it is measured off a deliberately weak year-ago base (NPM was just 1.09% then) and is not fully organic: the Process Equipment segment (JNK Chemdist), consolidated only from October 2025, was not present in the year-ago quarter at all, so the auditors themselves flag this quarter as not directly comparable to Q1FY25. Standalone tells a somewhat different, more modest story — standalone revenue grew 65.5% YoY to ₹163.55 Cr (versus 81.5% consolidated) and standalone PAT of ₹13.55 Cr actually exceeds the consolidated PAT of ₹9.63 Cr, because the newly-added Process Equipment subsidiary posted a segment loss and NCI absorbed part of the consolidated profit.
Q1 FY-2027 vs prior quarters
Margins compressed sharply sequentially: consolidated NPM fell to 5.35% from 9.59% in Q4FY26, and operating margin (EBITDA-based) eased to roughly 12.2% from Q4's 13.64% — both a function of Q4 being a seasonally back-loaded execution quarter for this project-driven EPC business, not a structural deterioration. Segment-wise, core Combustion Equipment did the heavy lifting with ₹163.71 Cr revenue and a ₹29.73 Cr segment profit, while Process Equipment added ₹16.25 Cr of revenue but a ₹1.33 Cr segment loss, consistent with a business still ramping post-acquisition.
The stock went into the print at ₹419.2, down 17.5% over the past month of trading.
JNK India provided a positive outlook with an expected revenue growth of 25% to 30% for FY27, supported by a strong order book and operational efficiencies. Management aims to maintain EBITDA margins in the 14%-15% range, reflecting a sustainable and achievable target. The company is strategically expanding its presenc
On guidance, management had targeted 25-30% FY27 revenue growth and a 14-15% EBITDA margin band off a FY26 consolidated revenue base of ₹818.55 Cr; this quarter's ~12.2% operating margin trails that band, and with only one (historically light) quarter in hand against a company whose revenue is heavily back-ended (Q4FY26 alone was nearly double this quarter's print), it is too early to call the full-year guidance met or missed — vsGuidance is marked unknown pending Q2-Q3 execution. No brokerage consensus for this specific quarter's revenue/PAT could be found in a web search, and JNK India has thin analyst coverage (effectively one tracked analyst); vsStreet is marked unknown rather than inferred. No standalone press release/management commentary accompanied this filing — that context is expected from the August 12, 2026 earnings call.
W1
FY27 guidance of 25-30% revenue growth and 14-15% EBITDA margin — Q1 operating margin (~12.2%) trails the band; watch Q2/Q3 for convergence toward guidance
W2
Process Equipment (Chemdist) segment is currently loss-making (₹1.33 Cr segment loss this quarter) — watch for its path to segment breakeven as it ramps post-acquisition
W3
Order-book impact of the TA'ZIZ Salt Project cancellation (July 16, 2026) on FY27 revenue visibility, despite management's stated 'no impact' on already-recognised numbers
Strong growth masked by guidance cuts, Chemdist drag
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Management hit prior quarter delivery targets. Now playing it safe with guidance cuts; acknowledged diversification execution risks explicitly.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order book (₹1,801 Cr) and pipeline (₹6,000 Cr) underpin 20-25% FY27 growth, but management cut prior guidance on both revenue and margins, signalling caution. Chemdist JV losses (₹3.6 Cr Q1) compress consolidated margins to 11.8% and order cancellation marks first execution risk in 15 years, though framed as licensor issue.
₹180 Cr
Revenue · +81.5% YoY₹9.6 Cr
Reported PAT · +754% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth guidance 20-25% remains intact
MISSPrior guidance was 25-30%, now lowered to 20-25%
EBITDA margin 12-14% maintained
OVERSTATEDPrior guidance 14-15%, now 12-14%; standalone achieved 14% but consolidated 11.8%
Strong YoY growth to ₹180 Cr, +81.5%
METDelivered ₹180 Cr revenue with 81.5% YoY growth
PAT grew 8.5x YoY to ₹9.6 Cr
METDelivered ₹9.6 Cr PAT with 754% YoY growth (~8.5x from low base)
Order cancellation exceptional, rare, no material loss
Partial1st cancellation in 15 years; early stage, no costs incurred; but shows licensor approval risk exists
Earnings quality
What changed since the last call
Revenue growth guidance cut
DowngradePrior 25-30% FY27 growth → now 20-25%; management frames as 'remains intact' but is clearly lower
EBITDA margin guidance cut
DowngradePrior 14-15% target → now 12-14%; Chemdist JV drag (operating loss ₹3.6 Cr Q1) cited; standalone achieved 14%
Bid pipeline expansion
UpgradePipeline grew ₹4,000 Cr → ₹6,000 Cr, 50% increase; mainly from new non-heating segments (metals, minerals, offshore)
Order cancellation disclosure
WithdrawnLarge export order (June 8) cancelled mid-execution due to licensor approval failure; no material cost; first such event in 15 years
The Q&A
Analysts pressed hard on diversification TAM, hit rates, and execution risks; also challenged guidance cuts. Management held firm on cautious 10-12% hit rate for new segments but was defensive on licensor approval risk and JNK Global legal issues.
Diversification revenue targets — Kamlesh Bagmar, Lotus Asset Managers
Answered20-25% annual growth medium-term; 3-5 year target is 40% non-heating revenue; entering new segments cautiously with smaller opportunities initially
Bid pipeline growth drivers — Deepak Purswani, SVAN Investments
AnsweredGrowth mainly from non-heating segment (₹3,000 Cr domestic new sectors: metals, minerals, renewable, oil & gas); export ₹3,000 Cr mostly heating; award expected 3-8 months timeline
EBITDA margin compression — Deepak Purswani, SVAN Investments
AnsweredGross margin improved; EBITDA compression due to Chemdist (₹3.6 Cr loss) and higher employee costs; standalone EBITDA 14% in line with guidance; temporary ramp-up effect
Raw material cost pass-through — Deepak Purswani, SVAN Investments
PartialOrders already placed at fixed prices with sub-vendors; commodity fluctuations not impacting ongoing project margins
New segment qualification risk — Nikhil Kanodia, Sunidhi Securities
AnsweredOffshore TAM $300-500M India; metals/minerals $500M-1B India; hit rate 10-12% in new segments (vs 20-25% heating); targeting ₹30-60M projects; will be bit cautious; need tech partners for qualification
JNK Global legal dispute impact — Rupesh Tatiya, Longequity Partners
DodgedNot comprehending any issues; JNK India capable to execute standalone if needed; no expected impact on order wins
Chemdist profitability timeline — Sahil Sanghvi, Monarch Networth Capital
PartialExpect to be in green by year-end FY27; cannot give exact number; plan is to get into green overall year-end figure
Guidance consistency — Kamlesh Bagmar, Lotus Asset Managers
DodgedAnnounced was 12-14%; no change from last 3-6 months; checking the numbers (acknowledges confusion)
Order cancellation risk mitigation — Kamlesh Bagmar, Lotus Asset Managers
PartialEPC contractor responsible for approval, not JNK; JNK now got qualification from licensor for future projects; more diligent checks planned; first time in 15 years; more accident than avoidable
Guidance
FY27 revenue growth 20-25% (vs prior 25-30%)
MediumDowngraded from prior guidance; supported by ₹1,801 Cr order book and ₹6,000 Cr pipeline with 20-25% hit rate on core heating
EBITDA margin 12-14% consolidated (vs prior 14-15%)
MediumCut reflects Chemdist JV temporary losses; standalone achieved 14%; expect improvement as JV scales
Risks the call surfaced
Order cancellation risk
HighLarge export order (June 8, 2026) cancelled due to licensor approval failure mid-execution. First event in 15 years. Shows execution risk even when JNK executes well.
Chemdist JV profitability
MediumJV operating loss ₹3.6 Cr in Q1 FY27; drags consolidated EBITDA from 14% to 11.8%. Expected to turn green by year-end but unproven. High fixed cost base is drag until revenue scales.
Diversification execution risk
MediumNew segments (metals/minerals, offshore, renewable) carry only 10-12% hit rate vs 20-25% for core heating. Requires technology partner qualification. First few projects high risk for qualification and margins.
Guidance downgrade credibility
MediumRevenue growth guidance cut from 25-30% to 20-25%; EBITDA margin guidance cut from 14-15% to 12-14%. Management frames as 'unchanged' which is misleading. Could signal underlying caution on pipeline conversion or margin headwinds.
JNK Global legal dispute spillover
LowActivist investor MJ Partners in dispute with JNK Global Board; matter sub judice. Could impact large order approvals requiring JNK Global's bank guarantees (especially Nigeria refinery project).
Management
Score 7/10. Clear on strategy and execution roadmap; candid on diversification risks (lower hit rates). Somewhat defensive on order cancellation and guidance cuts. Detailed on order book but vague on specific project timelines. Delivered on prior quarter results; order book solid at ₹1,801 Cr. First order cancellation in 15 years is red flag. Standalone margins hit guidance but JV losses dragging consolidated.
1 · Q2-Q3 FY27
Refinery and fertilizer order finalizations expected; Dangote Phase 2 repeat order still under discussion
2 · Q3-Q4 FY27
BPCL Bina execution ramps, significant revenue recognition; H2 typically 60-70% of annual revenue
3 · FY27 year-end
Chemdist expected to turn green; current ₹3.6 Cr quarterly loss becomes profitable
Chemdist JV losses (₹3.6 Cr Q1) compress consolidated margins to 11.8% and order cancellation marks first execution risk in 15 years, though framed as licensor issue.
Growth headlines hide margin cuts and JV drag — first order cancellation in 15 years
Revenue jumped 81.5% YoY but came off a low base (Q1 is just 10–15% of annual revenue). The real story: guidance cuts on revenue and margins, Chemdist JV losses of ₹3.6 Cr dragging consolidated EBITDA to 11.8%, and a landmark order cancellation signaling licensor approval risk.
The headline is bright: revenue of ₹180 Cr surged 81.5% year-on-year, and net profit jumped 754% to ₹9.6 Cr. But Q1 is just 10–15% of JNK's annual revenue — it's a seasonally small quarter — and the YoY base was depressed (₹99 Cr prior year). The real story sits underneath: management cut full-year revenue growth guidance from 25–30% to 20–25%, trimmed EBITDA margin guidance from 14–15% to 12–14%, and revealed that a consolidated EBITDA margin of 11.8% — 220 basis points below its standalone 14% — was dragged down by a ₹3.6 Cr operating loss in the Chemdist joint venture.
₹180 Cr
+81.5% YoY, -46.8% QoQ
₹9.6 Cr
+754% YoY, -70.9% QoQ
14%
in line with guidance
11.8%
below 12-14% guided
₹3.6 Cr
drags margin 14% → 11.8%
~₹210 Cr
forward visibility
Where the growth came from
The YoY surge is real in absolute terms — revenue grew from ₹99 Cr to ₹180 Cr — but the jump is amplified by a particularly weak prior-year quarter. Margins tell the story: the company achieved a 14% standalone EBITDA margin, which matches guidance, and net profit margin recovered to 5.2% from 1.1% a year earlier. The recovery is genuine. But consolidated profit was dragged by Chemdist (green hydrogen and sustainable fuels JV that contributed 8.8% of group revenue at ₹16 Cr but incurred an operating loss of ₹3.6 Cr). Management expects this to turn profitable by year-end, citing operating leverage as the JV scales revenue. The company also moved to input-based revenue recognition (from output-based), which pulled forward ₹210 Cr of unbilled revenue — a legitimate accounting change that signals forward visibility but also means some Q2–Q4 revenue is already on the books.
Management's claims vs. what holds up
"Revenue growth guidance of 20–25% remains intact"
ContradictedPrior guidance (FY-2026 call) was 25–30% for FY27. New guidance is now 20–25%. That is a cut of 5 percentage points.
"EBITDA margin guidance 12–14% maintained"
OverstatedPrior guidance was 14–15%; current is 12–14%. Standalone achieved 14%, but consolidated 11.8% due to Chemdist losses.
"Strong YoY growth to ₹180 Cr, +81.5%"
SupportedDelivered ₹180 Cr revenue, +81.5% vs ₹99 Cr prior year. Mathematically sound.
"PAT grew 8.5x to ₹9.6 Cr"
SupportedDelivered ₹9.6 Cr, +754% YoY (approximately 8.5x from a ₹1.2 Cr base).
"Order cancellation exceptional, rare, no material loss"
PartialFirst cancellation in 15 years; large export order cancelled mid-execution due to licensor approval failure. No costs incurred at early stage, but signals licensor approval risk exists.
What changed on this call
Bid pipeline expanded 50% to ₹6,000 Cr (from ₹4,000 Cr), mainly in new segments (metals, minerals, offshore, renewable)
Revenue and EBITDA margin guidance cut, not raised or maintained
Chemdist JV losses quantified at ₹3.6 Cr Q1; expected to turn profitable by year-end
First-ever order cancellation (large export order) disclosed; framed as licensor approval issue, not JNK execution failure
Entered Iraq market with registered office for oil & gas opportunities
Diversification to 40% non-heating revenue in 3–5 years announced; new segments carry 10–12% hit rate vs 20–25% for core heating
The bull-bear ledger
Order book ₹1,801 Cr provides 9–12 months revenue visibility; strong execution track record
Bid pipeline ₹6,000 Cr (50% expansion) with 50:50 domestic-export split reduces concentration risk
Standalone EBITDA margin 14% meets guidance despite higher employee costs
Refinery and petchem capex cycle in India and Africa (Nigeria) provides multi-year tailwinds
Guidance cuts on both revenue growth and EBITDA margin signal management has lost confidence in prior targets
Chemdist JV operating losses drag consolidated margin by 220 bps; turnaround unproven and dependent on revenue scaling
Order cancellation in large export deal — first in 15 years — proves even sound execution cannot protect against licensor approval failure
New segments (metals, minerals, offshore) carry half the hit rate of core heating; execution unproven
FII ownership fell to 0.94% from 1.17% (prior quarter); DII trimmed to 10.92% from 12.56% — smart money is exiting
Risks, ranked by how much they should concern a holder
Chemdist JV turnaround dependent on scaling revenue
HighJV incurred ₹3.6 Cr operating loss in Q1 (8.8% of group revenue), dragging consolidated EBITDA margin by 220 bps to 11.8% vs 14% standalone. Expected to be profitable by year-end, but the turnaround is unproven and depends on revenue scaling to offset fixed costs.
Licensor approval failures in export orders
HighLarge export order cancelled mid-execution due to licensor approval failure — first in 15 years. Management frames as rare and EPC contractor's responsibility, but even sound JNK execution cannot recover if licensor withholds approval. Export pipeline is 50% of ₹6,000 Cr bid; significant exposure.
Diversification execution risk in new segments
MediumNew segments (metals, minerals, offshore) carry 10–12% hit rate vs 20–25% for core heating. Requires technology partner qualifications. First few projects are high-risk for qualification failure and margin pressure. Diversification to 40% revenue in 3–5 years is aspirational; execution is unproven.
Guidance credibility after cuts
MediumManagement cut both revenue growth (25–30% → 20–25%) and EBITDA margin (14–15% → 12–14%), but framed the revenue cut as unchanged. Signals either underlying caution on pipeline conversion or margin headwinds. Analysts probed hard; management got defensive on licensor risk and JNK Global legal issues.
JNK Global legal dispute spillover
LowParent company (JNK Global) in dispute with activist investor; matter sub judice. Could impact large orders requiring parent bank guarantees (especially Nigeria refinery project). Management downplays risk, says JNK India can execute standalone.
How the street is positioned
The stock opened to a -2.85% drop on day 1 post-result, recovered to +8.84% by day 3, and held that pop at +10.68% by day 5. The market initially punished the guidance cuts and JV losses, but the strong order book and expanded pipeline persuaded buyers back in. The bounce has stuck: the stock now trades at ₹463.95, up from a 52-week low of ₹200.92 (+130.91% off the low) but down 16.85% from its all-time high of ₹558. Technically, it's above its 20-day average (₹441.4) but below its 50-day average (₹471.25) and well above its 200-day average (₹322.33); RSI at 51.5 signals equilibrium, not overbought.
Institutional flows tell a different story. FII ownership has fallen sharply to 0.94% from 1.17% in the prior quarter — a 23 basis point exit in one quarter — suggesting foreign investors are reducing exposure. DII ownership slipped to 10.92% from 12.56% (-164 bps), indicating domestic institutions are also trimming. Promoters remain locked in at 67.79%, showing no insider selling. Bulk deals in early June 2026 showed mixed activity in the ₹496–499 range, with no evidence of promoter-linked selling near the all-time high. The ownership shift is a red flag: while the market bounced on fundamentals, smart money is walking away.
The debate
What to watch next
1 · Q2–Q3 order finalizations (refinery, fertilizer, Nigeria repeat)
Management guided for awards expected in 3–8 months. Refinery and fertilizer orders finalization (especially BPCL Bina execution ramp and Dangote Phase 2 repeat order) will validate whether the ₹6,000 Cr pipeline converts at the 20–25% hit rate. Nigeria refinery project finalizations would confirm export strength despite the June cancellation.
2 · Chemdist profitability inflection by FY27 year-end
Management expects the JV to "be in green" by year-end. Q2–Q3 results will show whether losses are narrowing and whether the turnaround thesis holds. If losses persist or widen, it signals either revenue ramp-up delays or structural margin issues.
3 · Diversification traction in metals, minerals, offshore
New segment pipeline stands at ₹3,000 Cr (vs ₹3,000 Cr heating export). Tracking wins in metals/minerals (domestic) and offshore (emerging) in Q2–Q4 will show whether the 10–12% hit rate is realistic. First wins are critical to prove capability and margins.
The single number to track
Consolidated EBITDA margin in Q2 and beyond. If the Chemdist loss shrinks materially and margin approaches the 12–14% guidance range without further guidance cuts, the quarter's caution was justified. If margin stays at 11–12% or slides further, the diversification and JV strategy is hitting headwinds and the cuts were only the start. At ₹463.95 (trading near the 20-day average), the stock is neither rich nor cheap — fair value hinges on whether margins stabilize at guidance or deteriorate further.
JNK India delivered strong headline growth in a seasonally weak quarter, but that growth came off a low base. The real news is that management cut full-year guidance on revenue and margins, signalling caution ahead. The Chemdist JV drag is real and temporary; the order book is solid; and the pipeline has expanded. But the first order cancellation in 15 years and the lower hit rates in new segments are execution risks that governance and communication alone cannot resolve.
This is a hold for current holders and a wait-and-see for new entrants. The stock trades 16.85% below its all-time high, and FII/DII are both trimming positions. The next two quarters resolve whether Chemdist losses reverse and diversification gains traction. Until then, the debate remains open and the margin recovery is unproven.